US20230117587A1 - Wearable Injector with Adhesive Module - Google Patents
Wearable Injector with Adhesive Module Download PDFInfo
- Publication number
- US20230117587A1 US20230117587A1 US18/082,732 US202218082732A US2023117587A1 US 20230117587 A1 US20230117587 A1 US 20230117587A1 US 202218082732 A US202218082732 A US 202218082732A US 2023117587 A1 US2023117587 A1 US 2023117587A1
- Authority
- US
- United States
- Prior art keywords
- adhesive
- drug delivery
- delivery device
- housing
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000853 adhesive Substances 0.000 title claims abstract description 135
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 135
- 238000012377 drug delivery Methods 0.000 claims abstract description 52
- 239000000758 substrate Substances 0.000 claims abstract description 46
- 229940079593 drug Drugs 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 19
- -1 polypropylene Polymers 0.000 claims description 9
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 229920003051 synthetic elastomer Polymers 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000416 hydrocolloid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 3
- 229960001373 pegfilgrastim Drugs 0.000 claims description 3
- 108010044644 pegfilgrastim Proteins 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000005061 synthetic rubber Substances 0.000 claims description 3
- 229920000459 Nitrile rubber Polymers 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000005062 Polybutadiene Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 2
- 229910003460 diamond Inorganic materials 0.000 claims description 2
- 239000010432 diamond Substances 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 229920001194 natural rubber Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001084 poly(chloroprene) Polymers 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920002857 polybutadiene Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 description 7
- 239000002313 adhesive film Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000012858 resilient material Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950006925 emicizumab Drugs 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229950009792 mirikizumab Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
Definitions
- the present disclosure relates to drug delivery/infusion devices. More particularly, the present disclosure relates to devices mounted to the body for automatically delivering a drug to a patient. Even more particularly, the present disclosure relates devices mounted to the body of a patient, the device including a substrate including an adhesive for securing the substrate to the body of the patient and a second device including an adhesive for providing added adhesion of the device to the body of the patient.
- a device may be configured to deliver a drug over the span of 45 minutes, with delivery beginning 27 hours after the device has been activated and applied to a patient (to ensure that the drug is not delivered sooner than 24 hours after a medical procedure or treatment).
- FIGS. 1 and 2 One known on-body device 10 is shown in FIGS. 1 and 2 .
- the device 10 of FIG. 1 includes a housing 12 that contains or encloses the functional components of the device 10 , which are shown in FIGS. 3 and 4 .
- the internal components of the device 10 include a reservoir 14 that is configured to be filled with a liquid drug to be delivered to the patient.
- An upper surface of the housing 12 includes a fill indicator 16 that provides a visual indication of the amount of fluid in the reservoir 14 .
- the upper surface of the housing 12 may include printed information, such as information regarding the drug to be delivered.
- the upper surface of the housing 12 may be formed of a translucent material, which allows light from a status light 18 (which may be configured as a light-emitting diode) mounted within the housing 12 ( FIG. 1 ) to be seen through the upper surface of the housing 12 .
- the status light 18 is electrically coupled to a controller or processor (which may be a CPU or MPU configured as a computer chip mounted to a printed circuit board positioned within the housing 12 , for example) that carries software for executing a drug delivery routine.
- the status light 18 receives signals from the controller and emits light to provide information regarding a status of the device 10 . This may include emitting differently colored light and/or emitting light in different flashing patterns to indicate different conditions, such as a blinking orange light to indicate that the device 10 is ready to be applied to a patient, a blinking green light to indicate proper operation of the device 10 , and a blinking red light to indicate an error or other condition.
- One or more batteries 20 provide power to the status light 18 and the other electrical components of the device 10 .
- the drug is injected into the reservoir 14 using a (typically pre-filled) syringe 22 via a port 24 incorporated into the bottom or underside of the housing 12 ( FIG. 4 ) and fluidically connected to the reservoir 14 .
- FIGS. 1 and 2 illustrate an applicator 26 that is removably associated with the underside of the housing 12 and used in combination with the syringe 22 to fill the reservoir 14 via the port 24 .
- the drug is most typically injected into the reservoir 14 by a medical professional immediately before the device 10 is secured to the patient to ensure that the proper drug is supplied, along with the proper amount.
- a piston or plunger 28 ( FIG. 4 ) positioned within the reservoir 14 is moved (from left to right, in the orientation of FIG. 4 ) as the space within the reservoir 14 is filled by the inflowing drug. Movement of the piston 28 into its final position (when the reservoir 14 has been filled with the appropriate amount of the drug) causes a portion of a rod associated with the piston 28 to extend from the reservoir 14 to create an electrical connection, which activates the device 10 .
- Activation of the device 10 may include a signal, such as a buzzer providing an audible indication that the device 10 has been activated and/or a light emitted by the status light 18 .
- the device 10 When the device 10 has been activated, it is mounted or secured to the body of the patient.
- the applicator 26 is first removed from the underside of the housing 12 and discarded, followed by a pull tab 30 being manipulated to remove a release film from an adhesive pad 32 (substrate) associated with the underside of the housing 12 .
- the housing 12 is then pressed against the body of the patient, with the adhesive pad 32 (adhesive side of the substrate) facing the body.
- An adhesive present on the adhesive pad/substrate 32 causes the adhesive pad 32 (and, hence, the housing 12 ) to adhere to the body. Examples of devices using adhesive pads/substrates are described in U.S. Patent Application Publication 2019/0083702 and International Patent Application Publication WO2018/081234, the contents of which are incorporated by reference herein in their entireties.
- a distal end portion of a cannula 34 is introduced into the skin of the patient via a cannula window 36 defined in the housing 12 ( FIGS. 3 and 4 ).
- the cannula 34 (which remains partially positioned within the skin of the patient for as long as the device 10 is in use) is formed of a flexible or semi-rigid material, such as a plastic material, for improved patient comfort.
- an associated needle 38 is provided within the lumen of the cannula 34 , with a sharp or beveled distal end of the needle 38 extending out of a distal end of the cannula 34 .
- a midsection of the needle 38 is mounted within a needle carriage 40 , while a proximal end 42 of the cannula 34 is mounted within a cannula carriage 44 that is initially positioned directly adjacent to the needle carriage 40 .
- the needle carriage 40 is pivotally connected to an end of a linkage or crank arm 46 , with an opposite end of the linkage 46 being associated with a torsion spring 48 .
- the controller causes a lever (not visible) to be released, which allows the spring 48 to recoil, in turn rotating the linkage 46 , which rotation causes the needle carriage 40 to move along a linear track 50 from a first position adjacent to the spring 48 ( FIG. 3 ) to a second position spaced away from the spring 48 .
- Movement of the needle carriage 40 causes corresponding movement of the cannula carriage 44 along the track 50 , with the cannula 34 and the distal portion of the needle 38 moving together in a direction away from the spring 48 .
- Moving the carriages 40 and 44 into the second position causes the sharp distal end of the needle 38 to advance out of the housing 12 via the cannula window 36 and pierce the skin.
- the cannula 34 is carried by or moves along with the distal portion of the needle 38 , such that the needle 38 piercing the skin will also cause the distal end of the cannula 34 to enter into the skin.
- Movement of the needle carriage 40 in a proximal direction away from the cannula carriage 44 causes the needle 38 to partially (but not fully) retract from the cannula 34 .
- the distal end of the needle 38 is positioned within the cannula 34 (e.g., adjacent to a midsection or midpoint of the cannula 34 ), while the distal end of the cannula 34 remains positioned within the skin.
- a proximal end of the needle 38 extends into fluid communication with the reservoir 14 , such that the needle 38 provides a fluid path from the reservoir 14 to the cannula 34 when the carriages 40 and 44 are in the final condition illustrated in FIG. 3 .
- the distal end of the cannula 34 Due to the distal end of the cannula 34 remaining positioned within the skin, subsequent advancement of the drug out of the reservoir 14 (e.g., 27 hours after the device 10 has been activated) will cause the drug to move into the needle 38 (via the proximal end of the needle 38 ), through the needle 38 (to its distal end), and into the cannula 34 .
- the drug is then delivered to the patient (e.g., over the course of a 45-minute session) via the distal end of the cannula 34 positioned within the skin.
- the device 10 includes a lever 54 mounted to a pivot point 56 ( FIG. 4 ).
- the lever 54 includes a first arm 58 configured and oriented to interact with a first gear 60 and a second arm 62 configured and oriented to interact with a second gear 64 .
- a tab 66 extends from an opposite end of the lever 54 and is configured and oriented to alternately move into and out of contact with two electrical contacts 68 and 70 (electrically coupled to a printed circuit board, which is not shown) as the lever 54 pivots about the pivot point 56 .
- a first wire or filament 72 extends from the lever 54 , around a first pulley 74 , and into association with a first electrical contact 76 .
- a second wire or filament 78 extends from the lever 54 in the opposite direction of the first wire 72 , around a second pulley 80 , and into association with a second electrical contact 82 .
- the wires 72 and 78 (which are commonly referred to as “muscle wires”) are formed of a shape memory alloy (e.g., Nitinol), which causes them to heat up and contract when a current flows through them, while being allowed to stretch when the current is removed and the wire 72 , 78 cools.
- the controller provides commands that cause current to be alternately applied to the muscle wires 72 and 78 , which causes the lever 54 to alternately pivot about the pivot point 56 in opposite first and second directions. Pivotal movement of the lever 54 in the first direction will cause the first arm 58 of the lever 54 to engage and rotate the first gear 60 an incremental amount, while pivotal movement of the lever 54 in the second direction will cause the second arm 62 of the lever 54 to engage and rotate the second gear 64 an incremental amount (in the same direction in which the first gear 60 is rotated by the first arm 58 ). Both gears 60 and 64 are associated with a common shaft 84 (which is shown in FIG.
- gears 60 and 64 may be formed with gears 60 and 64 as a singled, molded piece), such that rotation of either gear 60 , 64 will cause the shaft 84 to rotate about its central axis.
- the shaft 84 is mechanically coupled to the piston 28 within the reservoir 14 , with rotation of the shaft 84 causing the piston 28 to move toward its initial position (e.g., by a threaded connection whereby rotation of the shaft 84 is translated into movement of the piston 28 along the length of the reservoir 14 ).
- the piston 28 moves toward its initial position (from right to left in the orientation of FIG. 4 )
- it will force the drug out of the reservoir 14 via the proximal end of the needle 38 .
- the drug will flow through the needle 38 , into and through the cannula 34 , and into the body of the patient.
- the controller alerts the patient via a visual cue from the status light 18 and/or an audible cue from the buzzer that drug delivery is complete. Subsequently, the patient removes the device 10 from their skin and discards the device 10 .
- the present disclosure is directed to an on-body drug delivery device including a housing with a cover and a bottom wall.
- the on-body drug delivery device includes a substrate made of a sheet of flexible material having a top surface and a bottom surface.
- the housing is carried by the substrate.
- the bottom of surface of the substrate includes an adhesive applied thereto.
- the on-body drug delivery device further includes an adhesive module disposed over at least a portion of the device.
- the adhesive module includes an adhesive on the bottom surface thereof.
- the adhesive module includes a film of flexible material having a top surface and a bottom surface, and a second adhesive applied to the bottom surface of said film.
- the adhesive module includes a support for the film.
- the support includes an internal frame.
- FIG. 1 is a top perspective view of a drug delivery device according to conventional design.
- FIG. 2 is a bottom perspective view of the drug delivery device of FIG. 1 .
- FIG. 3 is a top perspective view of the interior components of the drug delivery device of FIG. 1 .
- FIG. 4 is a bottom perspective view of the interior components of the drug delivery device of FIG. 1 .
- FIG. 5 is a perspective view of a drug delivery device for use in combination with the adhesive modules described herein.
- FIG. 6 A is an illustration showing the placement of a drug delivery device on the body of a patient.
- FIG. 6 B is an illustration showing an alternative placement of a drug delivery device on the body of a patient.
- FIG. 7 is a perspective view of a drug delivery device with an embodiment of an adhesive module in accordance with the present disclosure.
- FIG. 8 is a perspective view of a drug delivery device with another embodiment of an adhesive module in accordance with the present disclosure.
- FIG. 9 is a cross-sectional side view of the drug delivery device with the adhesive module of FIG. 8 .
- FIG. 10 is an exploded view of the drug delivery device with the adhesive module of FIG. 8 .
- FIG. 11 is a perspective view of a drug delivery device with another embodiment of an adhesive module in accordance with the present disclosure.
- FIG. 12 is a cross-sectional side view of the drug delivery device with the adhesive module of FIG. 11 .
- FIG. 13 is an exploded view of the drug delivery device with the adhesive module of FIG. 11 .
- FIG. 14 is a cross-sectional side view of a drug delivery device with an alternative embodiment of an adhesive module in accordance with the present disclosure.
- the wearable “on-body” drug delivery/infusion device 10 (which may have a modular construction) comprises a main body or housing 90 that houses many of the electro-mechanical components of the device and a removable cartridge that is pre-filled and/or refillable with a drug.
- a removable cartridge (not shown) permits re-filling and reuse of the infuser without having to remove it from the patient after the initial attachment and permits the device to be used to deliver more than one type of drug.
- a separable pre-filled cartridge also facilitates storage of the drug (which would be refrigerated) apart from the main body/housing 90 , which may be stored at room temperature, thus reducing the amount of refrigerated storage space required.
- the cartridge further comprises a pre-filled drug chamber, a piston/plunger, and a structure for pressurizing the drug held within the chamber for delivery to the patient. While a removable cartridge may be advantageous, it is also within the scope of the present disclosure for the device to be provided as a single-use item, with a pre-filled or fillable drug chamber or reservoir, as in conventional devices.
- Housing 90 is affixed to and carried by a substrate 100 which may be affixed or adhered to the patient's body.
- substrate 100 may take the form of a flat sheet or pad having a top surface 102 and a bottom surface 104 and further defined by a peripheral edge 106 .
- Substrate 100 may have a rectangular shape with rounded corners, as shown in FIG. 5 , or any other suitable shape and size that can accommodate housing 90 , In this regard, it may be preferable that substrate 100 includes a dimension, such as surface area, that is greater than the surface area of a bottom wall of housing 90 , thereby defining a perimeter 108 between the outside edge of housing 90 and peripheral edge 106 of substrate 100 .
- Substrate 100 is preferably made of a flexible, resilient material that can be stretched.
- Substrate 100 may further include upper and lower bacteria impermeable liners as described in US Patent Application Publication No. 2019/0083702, the contents of which are incorporated herein by reference,
- the exposed surface of peripheral edge may likewise include and be covered by a bacterial impermeable liner.
- the flexible, resilient material of substrate 100 may be any such material that can be safely applied and adhered to the skin of the patient.
- substrate 100 is made of non-woven, fibrous material.
- suitable materials include polyethylene, polyvinyl chloride, polyurethane, polyethylene terephthalate, polypropylene, viscose/rayon, thermoplastic elastomer and the like.
- drug delivery device 10 may be worn by the patient (on, for example, the arm or torso) where it is affixed or adhered to the skin of the patient.
- substrate 100 may include or be otherwise provided with an adhesive on bottom surface 104 .
- the adhesive is such that the substrate remains adhered to the patient's body and, preferably, cannot be easily dislodged or separated from the patient's skin.
- the adhesive should be waterproof and/or resistant to degradation by perspiration.
- adhesive substrate 100 should tightly conform to the skin of the patient to keep the needle of the device from dislodging.
- the adhesive is not permanent and, when necessary, can be removed routinely by a medical professional in an “out-patient” procedure or even by the patient.
- suitable adhesives useful with substrates of the type described herein include any medical-grade or skin contact adhesives such as, but not limited to, acrylic or acrylate compositions, synthetic rubber, hydrocolloid, silicone and the like.
- device 10 may be provided with a separate adhesive module for securing device 10 to the body of the patient.
- a separate adhesive module for securing device 10 to the body of the patient.
- an adhesive module of the type described herein in combination with a device that already includes an adhesive on the bottom surface of a substrate provides an added degree of confidence that device 10 will remain secured during the duration of the drug delivery.
- adhesive modules of the type described herein ensure that the device will remain in contact with the patient. Adhesive modules of the type described herein may also help prevent leakage caused by partial dislodgement of device 10 .
- Using a “dual adhesive” approach i.e., adhesive on the substrate 100 and a second adhesive on the adhesive module
- a dual adhesive approach allows for replacement or a refreshment of the adhesive module without having to remove device 10 .
- a dual adhesive approach may also require less adhesive on device substrate 100 , making ultimate removal of device 10 from the skin easier on the patient.
- adhesive module 140 may be an “over adhesive” member that is applied over and on top of at least a portion of device 10 , including housing 90 and substrate 100 .
- adhesive module 140 may be a sheet of stretchable adhesive film 142 placed over device 10 and secured to device 10 at selected points.
- Film 142 may be sized and shaped such that it can be stretched to extend beyond the perimeter 108 of substrate 100 and attach to the skin of the patient.
- bottom surface 144 of film 142 may include an adhesive layer or coating.
- adhesive module 140 may be sized and shaped to cover at least a portion of device 10 and extend beyond the perimeter 108 of substrate 100 for adhesive attachment to the skin of the patient.
- adhesive module 140 is shown as a cross-shaped sheet with a central portion 148 placed over (and adhered to) housing 90 with end tab portions 150 and side tab portions 152 extending from the central portion 148 over and beyond substrate perimeter 108 .
- tab portions 150 and 152 may be pulled and stretched to attach adhesive module 140 to the skin of the patient.
- the adhesive modules described herein may have other shapes and configurations (such as an oval, rectangle, diamond, or even multiple strips or pieces) provided that, when applied over device 10 , they extend beyond the perimeter 108 of substrate 100 to allow for contact with the patient's skin.
- FIGS. 8 - 10 show an alternative embodiment of an adhesive module in accordance with the present disclosure.
- Adhesive module 160 of FIGS. 8 - 10 is a ringed member that defines a central opening 162 for receiving a portion of device 10 .
- central opening 162 is sized and shaped to receive housing 90 of device 10 .
- Adhesive module 160 may be an overlay that is placed over drug delivery device 10 , as best seen in FIG. 10 .
- Central opening 162 may be configured such that housing 90 fits snugly within the central opening,
- Adhesive module 160 may further include a support member or structure 164 to better align module 160 with drug delivery device 10 and/or to provide a surface to which drug delivery device 10 may be releasably attached by, for example snap-fit, press-fit or detent engagement.
- support structure 164 is preferably made of a sufficiently rigid material including, but not limited to, plastic polymers such as polyvinyl chloride (PVC), polypropylene, polycarbonate and polystyrene.
- PVC polyvinyl chloride
- support structure 164 may be a rigid frame or framework defining openings 167 therein.
- Support structure 164 may also be a screen or lattice-like structure or a solid ring to which an adhesive film is attached, as will be described below.
- Support structure 164 may be injection molded or may be assembled from a plurality of sealed-together porous or solid sheets to form a composite structure having the desired rigidity to receive and align with drug delivery device 10 .
- Adhesive module 160 further includes an adhesive film 166 attached (adhered) and conformed to support structure 164 as shown in FIGS. 8 - 10 to provide a single module.
- Adhesive film 166 includes a top non-adhesive surface 168 and a bottom surface 170 with adhesive applied thereon as a coating or layer 172 of adhesive as shown in FIG. 9 .
- film 166 is conformed to support structure 164 with bottom surface 170 adhered to the solid or rigid portion of support structure 164 .
- Film 166 extends beyond the peripheral edge 174 of structure 164 and, once device 10 is attached to the patient, beyond the outer edge of perimeter 108 where adhesive module 160 can be directly adhered to patient's skin as shown in FIG. 9 .
- FIGS. 11 - 13 A further embodiment of an adhesive module in accordance with the present disclosure is shown in FIGS. 11 - 13 .
- the embodiment of adhesive module 180 in FIGS. 11 - 13 is, in many respects, similar to the above-described embodiment of FIGS. 8 - 10 in that adhesive module 180 likewise includes a support structure 182 .
- support structure 182 may be an internal frame or framework as shown in FIGS. 8 - 10 with a film 184 conformed thereto, as best seen in FIG. 12 . More specifically, support structure 182 may be a frame or framework defining openings 183 therein. Support structure 182 may also be a screen or lattice-like structure or a solid ring to which an adhesive film 184 is attached, as will be described below.
- Support structure 182 may be injection molded or may be assembled from a plurality of sealed-together porous or solid sheets to form a composite structure having the desired rigidity to receive and align with drug delivery device 10 .
- Film 184 includes a top non adhesive surface 186 and a bottom surface 188 with adhesive applied thereon as a coating or layer. As shown in FIGS. 11 and 13 , film 184 is adhered to housing 90 and provides a full covering over device 10 . As in earlier embodiments, film 184 extends beyond the peripheral edge 190 of structure 182 and, once device 10 is attached to the patient, beyond the outer edge of perimeter 108 where adhesive module 180 can be directly adhered to patient's skin as shown in FIG. 12 .
- the on-body drug delivery device described herein utilizes a “dual adhesive” approach, namely, an adhesive on the bottom surface of the device substrate 10 and an adhesive on the bottom surface of the film that is part of the adhesive module 140 , 160 , 180 .
- the adhesive of the adhesive module likewise contacts the skin of the patient, the adhesive must be one that allows the adhesive module to remain adhered to the patient's body and, preferably, cannot be easily dislodged or separated from the patient's skin.
- the adhesive of the adhesive module should be waterproof and/or resistant to degradation by perspiration.
- adhesive substrate should tightly conform to the skin of the patient to keep the needle of the device from dislodging.
- the adhesive is not permanent and, when necessary, can be removed routinely by a medical professional in an “out-patient” procedure or even by the patient.
- the adhesive may also contact and adhere to the delivery device (as in the embodiments of FIGS. 7 and 11 - 13 ) or may contact a support structure (as in the embodiments of FIGS. 8 - 14 )
- the adhesive should have good adhesion to the materials used for the device 10 and support structures 164 , 182 .
- suitable adhesives for both skin and such non-skin adhesion include, but are not limited to, acrylic or acrylate compositions, synthetic rubber, hydrocolloid, silicone and the like.
- the adhesive applied to the adhesive module may be formed of the same material or materials as the adhesive applied to the adhesive applied to the substrate of the device 10 or a different material or materials.
- an adhesive module to include a plurality of different adhesives that are particularly configured for adhesion to either a skin or a non-skin surface.
- an adhesive that is particularly well-suited to adhesion to a non-skin surface may be applied to a region of the adhesive module configured to engage the device 10
- a different adhesive that is particularly well-suited to adhesion of a skin surface may be applied to a region of the adhesive module configured to engage the skin of the patient.
- An adhesive configured to engage a surface of the device 10 may be configured to be relatively weak (allowing for dissociation of the device and adhesive module) or strong (to discourage or prevent dissociation of the device and adhesive module).
- adhesive may be applied to only a portion of the bottom surface 188 of film 184 which covers and overlies the drug delivery device.
- the portion of film 184 that covers the device (housing 90 ) may be free of adhesive.
- adhesive 188 may be applied only to the outer peripheral region of film 184 of adhesive module 200 that is coincident with support structure 202 and in contact with the patient's skin.
- adhesive may be applied to a peripheral region of the bottom surface 188 of film 184 that contacts only a portion of support structure 202 and the patient's skin (not shown).
- adhesive may be applied only to that portion of film 184 that contacts the skin of the patient (not shown).
- Films 142 , 166 , 184 described above may be made of any flexible, stretchable material that is suited for use with the adhesives described herein.
- film 184 (with or without adhesive) may conform closely to the contour of device (housing 90 ) as shown, for example, in FIG. 14 .
- film (with or without adhesive) may cover device (housing 90 ) in a less conforming manner as shown, for example, in FIG. 12 .
- Suitable film materials include, but are not limited to, polyethylene, polypropylene, polyurethanes, polyamides, polyesters, ethylene vinyl acetate, natural or synthetic polyisoprene, polybutadiene, polychloroprene, silicone, nitrile rubbers, nylon, olefin, and polyvinyl chloride.
- the drug delivery devices described herein may be used to deliver any suitable fluid medication to a subject.
- the methods and devices described herein are used to deliver pegfilgrastim to a subject, though other exemplary medications include (without limitation) one or more of the following: adalimiumab, rituximab, risankizumab, etanercept, trastuzumab, ado-trastuzumab emtansine, trastuzumab deruxtecan, bevacizumab, infliximab, pegfilgrastim, filgrastim, tocilizumab, golimumab, interferon beta-1a, ranibizumab, denosumab, pembrolizumab, nivolumab, aflibercept, eculizumab, ocrelizumab, pertuzumab, secukinumab, omalizumab, ustekinum
Abstract
Description
- This application is a divisional of U.S. patent application Ser. No. 17/246,297, filed Apr. 30, 2021, the contents of which are hereby incorporated by reference.
- The present disclosure relates to drug delivery/infusion devices. More particularly, the present disclosure relates to devices mounted to the body for automatically delivering a drug to a patient. Even more particularly, the present disclosure relates devices mounted to the body of a patient, the device including a substrate including an adhesive for securing the substrate to the body of the patient and a second device including an adhesive for providing added adhesion of the device to the body of the patient.
- Delivery of liquid drugs to a patient via injection using a needle or syringe is well-known. More recently, devices that automate the delivery of liquid drugs have been introduced. These devices (which are commonly referred to as “on-body devices” or “on-body injectors”) are mounted or otherwise secured to the body of the patient (e.g., to the arm or abdomen) and remain in place for an extended amount of time (on the order of hours or days), injecting an amount of the drug into the body of the patient at one or more scheduled times. For example, a device may be configured to deliver a drug over the span of 45 minutes, with delivery beginning 27 hours after the device has been activated and applied to a patient (to ensure that the drug is not delivered sooner than 24 hours after a medical procedure or treatment). These devices improve upon manual methods by obviating the need for the patient to inject themselves with the drug (which carries heightened risks of the patient improperly administering the injection or injecting the drug at an inappropriate time) or to return to a medical facility for one or more injections by a technician or medical professional.
- One known on-
body device 10 is shown inFIGS. 1 and 2 . Thedevice 10 ofFIG. 1 includes ahousing 12 that contains or encloses the functional components of thedevice 10, which are shown inFIGS. 3 and 4 . - The internal components of the
device 10 include areservoir 14 that is configured to be filled with a liquid drug to be delivered to the patient. An upper surface of thehousing 12 includes afill indicator 16 that provides a visual indication of the amount of fluid in thereservoir 14. In addition to thefill indicator 16, the upper surface of thehousing 12 may include printed information, such as information regarding the drug to be delivered. The upper surface of thehousing 12 may be formed of a translucent material, which allows light from a status light 18 (which may be configured as a light-emitting diode) mounted within the housing 12 (FIG. 1 ) to be seen through the upper surface of thehousing 12. Thestatus light 18 is electrically coupled to a controller or processor (which may be a CPU or MPU configured as a computer chip mounted to a printed circuit board positioned within thehousing 12, for example) that carries software for executing a drug delivery routine. Thestatus light 18 receives signals from the controller and emits light to provide information regarding a status of thedevice 10. This may include emitting differently colored light and/or emitting light in different flashing patterns to indicate different conditions, such as a blinking orange light to indicate that thedevice 10 is ready to be applied to a patient, a blinking green light to indicate proper operation of thedevice 10, and a blinking red light to indicate an error or other condition. One ormore batteries 20 provide power to thestatus light 18 and the other electrical components of thedevice 10. - The drug is injected into the
reservoir 14 using a (typically pre-filled)syringe 22 via aport 24 incorporated into the bottom or underside of the housing 12 (FIG. 4 ) and fluidically connected to thereservoir 14.FIGS. 1 and 2 illustrate anapplicator 26 that is removably associated with the underside of thehousing 12 and used in combination with thesyringe 22 to fill thereservoir 14 via theport 24. The drug is most typically injected into thereservoir 14 by a medical professional immediately before thedevice 10 is secured to the patient to ensure that the proper drug is supplied, along with the proper amount. - A piston or plunger 28 (
FIG. 4 ) positioned within thereservoir 14 is moved (from left to right, in the orientation ofFIG. 4 ) as the space within thereservoir 14 is filled by the inflowing drug. Movement of thepiston 28 into its final position (when thereservoir 14 has been filled with the appropriate amount of the drug) causes a portion of a rod associated with thepiston 28 to extend from thereservoir 14 to create an electrical connection, which activates thedevice 10. Activation of thedevice 10 may include a signal, such as a buzzer providing an audible indication that thedevice 10 has been activated and/or a light emitted by thestatus light 18. - When the
device 10 has been activated, it is mounted or secured to the body of the patient. Theapplicator 26 is first removed from the underside of thehousing 12 and discarded, followed by apull tab 30 being manipulated to remove a release film from an adhesive pad 32 (substrate) associated with the underside of thehousing 12. Thehousing 12 is then pressed against the body of the patient, with the adhesive pad 32 (adhesive side of the substrate) facing the body. An adhesive present on the adhesive pad/substrate 32 causes the adhesive pad 32 (and, hence, the housing 12) to adhere to the body. Examples of devices using adhesive pads/substrates are described in U.S. Patent Application Publication 2019/0083702 and International Patent Application Publication WO2018/081234, the contents of which are incorporated by reference herein in their entireties. - Some predetermined time after the
device 10 has been activated (which may be on the order of three to five minutes, for example), a distal end portion of acannula 34 is introduced into the skin of the patient via acannula window 36 defined in the housing 12 (FIGS. 3 and 4 ). The cannula 34 (which remains partially positioned within the skin of the patient for as long as thedevice 10 is in use) is formed of a flexible or semi-rigid material, such as a plastic material, for improved patient comfort. - As the
cannula 34 is not itself configured to pierce the skin, an associatedneedle 38 is provided within the lumen of thecannula 34, with a sharp or beveled distal end of theneedle 38 extending out of a distal end of thecannula 34. A midsection of theneedle 38 is mounted within aneedle carriage 40, while aproximal end 42 of thecannula 34 is mounted within a cannula carriage 44 that is initially positioned directly adjacent to theneedle carriage 40. Theneedle carriage 40 is pivotally connected to an end of a linkage orcrank arm 46, with an opposite end of thelinkage 46 being associated with atorsion spring 48. At the designated time (e.g., 3-5 minutes after thedevice 10 has been activated), the controller causes a lever (not visible) to be released, which allows thespring 48 to recoil, in turn rotating thelinkage 46, which rotation causes theneedle carriage 40 to move along alinear track 50 from a first position adjacent to the spring 48 (FIG. 3 ) to a second position spaced away from thespring 48. Movement of theneedle carriage 40 causes corresponding movement of the cannula carriage 44 along thetrack 50, with thecannula 34 and the distal portion of theneedle 38 moving together in a direction away from thespring 48. Moving thecarriages 40 and 44 into the second position causes the sharp distal end of theneedle 38 to advance out of thehousing 12 via thecannula window 36 and pierce the skin. Thecannula 34 is carried by or moves along with the distal portion of theneedle 38, such that theneedle 38 piercing the skin will also cause the distal end of thecannula 34 to enter into the skin. - Continued recoiling of the
spring 48 causes further rotation of thelinkage 46, which has the effect of moving theneedle carriage 40 back toward the spring 48 (i.e., back toward its first position). Rather than moving along with theneedle carriage 40, the cannula carriage 44 is held in its second position (FIG. 3 ) by a lock orlatch 52, As the movement of theneedle carriage 40 is not restricted by the lock orlatch 52, theneedle carriage 40 will return to its first position, while the cannula carriage 44 remains in its second position (with the final positions of bothcarriages 40 and 44 shown inFIG. 3 ). - Movement of the
needle carriage 40 in a proximal direction away from the cannula carriage 44 causes theneedle 38 to partially (but not fully) retract from thecannula 34. In the final condition shown inFIG. 3 , the distal end of theneedle 38 is positioned within the cannula 34 (e.g., adjacent to a midsection or midpoint of the cannula 34), while the distal end of thecannula 34 remains positioned within the skin. A proximal end of theneedle 38 extends into fluid communication with thereservoir 14, such that theneedle 38 provides a fluid path from thereservoir 14 to thecannula 34 when thecarriages 40 and 44 are in the final condition illustrated inFIG. 3 . Due to the distal end of thecannula 34 remaining positioned within the skin, subsequent advancement of the drug out of the reservoir 14 (e.g., 27 hours after thedevice 10 has been activated) will cause the drug to move into the needle 38 (via the proximal end of the needle 38), through the needle 38 (to its distal end), and into thecannula 34. The drug is then delivered to the patient (e.g., over the course of a 45-minute session) via the distal end of thecannula 34 positioned within the skin. - As for the mechanism by which the drug is advanced out of the
reservoir 14, thedevice 10 includes alever 54 mounted to a pivot point 56 (FIG. 4 ). Thelever 54 includes afirst arm 58 configured and oriented to interact with afirst gear 60 and asecond arm 62 configured and oriented to interact with asecond gear 64. Atab 66 extends from an opposite end of thelever 54 and is configured and oriented to alternately move into and out of contact with twoelectrical contacts 68 and 70 (electrically coupled to a printed circuit board, which is not shown) as thelever 54 pivots about thepivot point 56. - A first wire or
filament 72 extends from thelever 54, around afirst pulley 74, and into association with a firstelectrical contact 76. A second wire orfilament 78 extends from thelever 54 in the opposite direction of thefirst wire 72, around asecond pulley 80, and into association with a secondelectrical contact 82. Thewires 72 and 78 (which are commonly referred to as “muscle wires”) are formed of a shape memory alloy (e.g., Nitinol), which causes them to heat up and contract when a current flows through them, while being allowed to stretch when the current is removed and thewire wires wire lever 54, causing it to pivot about thepivot point 56. Thus, alternately applying current to the twowires wires lever 54 to pivot back and forth about thepivot point 56. - At the designated time (e.g., 27 hours after the
device 10 has been activated), the controller provides commands that cause current to be alternately applied to themuscle wires lever 54 to alternately pivot about thepivot point 56 in opposite first and second directions. Pivotal movement of thelever 54 in the first direction will cause thefirst arm 58 of thelever 54 to engage and rotate thefirst gear 60 an incremental amount, while pivotal movement of thelever 54 in the second direction will cause thesecond arm 62 of thelever 54 to engage and rotate thesecond gear 64 an incremental amount (in the same direction in which thefirst gear 60 is rotated by the first arm 58). Bothgears FIG. 3 and may be formed withgears gear shaft 84 to rotate about its central axis. Theshaft 84 is mechanically coupled to thepiston 28 within thereservoir 14, with rotation of theshaft 84 causing thepiston 28 to move toward its initial position (e.g., by a threaded connection whereby rotation of theshaft 84 is translated into movement of thepiston 28 along the length of the reservoir 14). As thepiston 28 moves toward its initial position (from right to left in the orientation ofFIG. 4 ), it will force the drug out of thereservoir 14 via the proximal end of theneedle 38. As described above, the drug will flow through theneedle 38, into and through thecannula 34, and into the body of the patient. - After the drug has been delivered (e.g., over the course of a 45-minute session), the controller alerts the patient via a visual cue from the
status light 18 and/or an audible cue from the buzzer that drug delivery is complete. Subsequently, the patient removes thedevice 10 from their skin and discards thedevice 10. - While devices of the type described above have proven adequate, there remains room for improvement. For example, while the substrate that carries the device also secures the device to the patient's skin, additional points of attachment may be desired. In that regard, it would be beneficial to provide an additional means for securing the device to the body of the patient which can preferably be replaced and/or refreshed without removing the device.
- There are several aspects of the present subject matter which may be embodied separately or together in the devices and systems described and claimed below. These aspects may be employed alone or in combination with other aspects of the subject matter described herein, and the description of these aspects together is not intended to preclude the use of these aspects separately or the claiming of such aspects separately or in different combinations as set forth in the claims appended hereto.
- In one aspect, the present disclosure is directed to an on-body drug delivery device including a housing with a cover and a bottom wall. The on-body drug delivery device includes a substrate made of a sheet of flexible material having a top surface and a bottom surface. The housing is carried by the substrate. The bottom of surface of the substrate includes an adhesive applied thereto. The on-body drug delivery device further includes an adhesive module disposed over at least a portion of the device. The adhesive module includes an adhesive on the bottom surface thereof.
- In another aspect, the adhesive module includes a film of flexible material having a top surface and a bottom surface, and a second adhesive applied to the bottom surface of said film.
- In a further aspect, the adhesive module includes a support for the film.
- In a more particular aspect, the support includes an internal frame.
-
FIG. 1 is a top perspective view of a drug delivery device according to conventional design. -
FIG. 2 is a bottom perspective view of the drug delivery device ofFIG. 1 . -
FIG. 3 is a top perspective view of the interior components of the drug delivery device ofFIG. 1 . -
FIG. 4 is a bottom perspective view of the interior components of the drug delivery device ofFIG. 1 . -
FIG. 5 is a perspective view of a drug delivery device for use in combination with the adhesive modules described herein. -
FIG. 6A is an illustration showing the placement of a drug delivery device on the body of a patient. -
FIG. 6B is an illustration showing an alternative placement of a drug delivery device on the body of a patient. -
FIG. 7 is a perspective view of a drug delivery device with an embodiment of an adhesive module in accordance with the present disclosure. -
FIG. 8 is a perspective view of a drug delivery device with another embodiment of an adhesive module in accordance with the present disclosure, -
FIG. 9 is a cross-sectional side view of the drug delivery device with the adhesive module ofFIG. 8 . -
FIG. 10 is an exploded view of the drug delivery device with the adhesive module ofFIG. 8 . -
FIG. 11 is a perspective view of a drug delivery device with another embodiment of an adhesive module in accordance with the present disclosure. -
FIG. 12 is a cross-sectional side view of the drug delivery device with the adhesive module ofFIG. 11 . -
FIG. 13 is an exploded view of the drug delivery device with the adhesive module ofFIG. 11 . -
FIG. 14 is a cross-sectional side view of a drug delivery device with an alternative embodiment of an adhesive module in accordance with the present disclosure. - The embodiments disclosed herein are for the purpose of providing a description of the present subject matter, and it is understood that the subject matter may be embodied in various other forms and combinations not shown in detail. Therefore, specific designs and features disclosed herein are not to be interpreted as limiting the subject matter as defined in the accompanying claims.
- In keeping with the present disclosure, and with reference to
FIG. 5 , the wearable “on-body” drug delivery/infusion device 10 (which may have a modular construction) comprises a main body orhousing 90 that houses many of the electro-mechanical components of the device and a removable cartridge that is pre-filled and/or refillable with a drug. A removable cartridge (not shown) permits re-filling and reuse of the infuser without having to remove it from the patient after the initial attachment and permits the device to be used to deliver more than one type of drug. A separable pre-filled cartridge also facilitates storage of the drug (which would be refrigerated) apart from the main body/housing 90, which may be stored at room temperature, thus reducing the amount of refrigerated storage space required. The cartridge further comprises a pre-filled drug chamber, a piston/plunger, and a structure for pressurizing the drug held within the chamber for delivery to the patient. While a removable cartridge may be advantageous, it is also within the scope of the present disclosure for the device to be provided as a single-use item, with a pre-filled or fillable drug chamber or reservoir, as in conventional devices. -
Housing 90 is affixed to and carried by asubstrate 100 which may be affixed or adhered to the patient's body. As shown inFIG. 5 ,substrate 100 may take the form of a flat sheet or pad having atop surface 102 and abottom surface 104 and further defined by aperipheral edge 106.Substrate 100 may have a rectangular shape with rounded corners, as shown inFIG. 5 , or any other suitable shape and size that can accommodatehousing 90, In this regard, it may be preferable thatsubstrate 100 includes a dimension, such as surface area, that is greater than the surface area of a bottom wall ofhousing 90, thereby defining aperimeter 108 between the outside edge ofhousing 90 andperipheral edge 106 ofsubstrate 100. -
Substrate 100 is preferably made of a flexible, resilient material that can be stretched.Substrate 100 may further include upper and lower bacteria impermeable liners as described in US Patent Application Publication No. 2019/0083702, the contents of which are incorporated herein by reference, The exposed surface of peripheral edge may likewise include and be covered by a bacterial impermeable liner. - The flexible, resilient material of
substrate 100 may be any such material that can be safely applied and adhered to the skin of the patient. Typically,substrate 100 is made of non-woven, fibrous material. Examples of suitable materials include polyethylene, polyvinyl chloride, polyurethane, polyethylene terephthalate, polypropylene, viscose/rayon, thermoplastic elastomer and the like. - As shown in
FIGS. 6A and 6B ,drug delivery device 10 may be worn by the patient (on, for example, the arm or torso) where it is affixed or adhered to the skin of the patient. In one embodiment,substrate 100 may include or be otherwise provided with an adhesive onbottom surface 104. The adhesive is such that the substrate remains adhered to the patient's body and, preferably, cannot be easily dislodged or separated from the patient's skin. In that regard, the adhesive should be waterproof and/or resistant to degradation by perspiration. In addition,adhesive substrate 100 should tightly conform to the skin of the patient to keep the needle of the device from dislodging. At the same time, the adhesive is not permanent and, when necessary, can be removed routinely by a medical professional in an “out-patient” procedure or even by the patient. Examples of suitable adhesives useful with substrates of the type described herein include any medical-grade or skin contact adhesives such as, but not limited to, acrylic or acrylate compositions, synthetic rubber, hydrocolloid, silicone and the like. - In accordance with the present disclosure,
device 10 may be provided with a separate adhesive module for securingdevice 10 to the body of the patient. Using an adhesive module of the type described herein in combination with a device that already includes an adhesive on the bottom surface of a substrate provides an added degree of confidence thatdevice 10 will remain secured during the duration of the drug delivery. In the event thatdevice 10 does become partially dislodged from the skin of the patient, adhesive modules of the type described herein ensure that the device will remain in contact with the patient. Adhesive modules of the type described herein may also help prevent leakage caused by partial dislodgement ofdevice 10. Using a “dual adhesive” approach (i.e., adhesive on thesubstrate 100 and a second adhesive on the adhesive module) allows for replacement or a refreshment of the adhesive module without having to removedevice 10. A dual adhesive approach may also require less adhesive ondevice substrate 100, making ultimate removal ofdevice 10 from the skin easier on the patient. - Turning now to
FIG. 7 , a first embodiment ofadhesive module 140 is shown. As shown inFIG. 7 ,adhesive module 140 may be an “over adhesive” member that is applied over and on top of at least a portion ofdevice 10, includinghousing 90 andsubstrate 100. In the embodiment ofFIG. 7 ,adhesive module 140 may be a sheet of stretchableadhesive film 142 placed overdevice 10 and secured todevice 10 at selected points.Film 142 may be sized and shaped such that it can be stretched to extend beyond theperimeter 108 ofsubstrate 100 and attach to the skin of the patient. In that regard,bottom surface 144 offilm 142 may include an adhesive layer or coating. - As noted above,
adhesive module 140 may be sized and shaped to cover at least a portion ofdevice 10 and extend beyond theperimeter 108 ofsubstrate 100 for adhesive attachment to the skin of the patient. In the embodiment ofFIG. 7 ,adhesive module 140 is shown as a cross-shaped sheet with acentral portion 148 placed over (and adhered to)housing 90 withend tab portions 150 andside tab portions 152 extending from thecentral portion 148 over and beyondsubstrate perimeter 108. During placement,tab portions adhesive module 140 to the skin of the patient. Of course, it will be understood that the adhesive modules described herein may have other shapes and configurations (such as an oval, rectangle, diamond, or even multiple strips or pieces) provided that, when applied overdevice 10, they extend beyond theperimeter 108 ofsubstrate 100 to allow for contact with the patient's skin. -
FIGS. 8-10 show an alternative embodiment of an adhesive module in accordance with the present disclosure.Adhesive module 160 ofFIGS. 8-10 is a ringed member that defines acentral opening 162 for receiving a portion ofdevice 10. In the case ofFIG. 8 ,central opening 162 is sized and shaped to receivehousing 90 ofdevice 10.Adhesive module 160 may be an overlay that is placed overdrug delivery device 10, as best seen inFIG. 10 .Central opening 162 may be configured such thathousing 90 fits snugly within the central opening, -
Adhesive module 160 may further include a support member orstructure 164 to better alignmodule 160 withdrug delivery device 10 and/or to provide a surface to whichdrug delivery device 10 may be releasably attached by, for example snap-fit, press-fit or detent engagement. Accordingly,support structure 164 is preferably made of a sufficiently rigid material including, but not limited to, plastic polymers such as polyvinyl chloride (PVC), polypropylene, polycarbonate and polystyrene. As shown inFIG. 8 andFIG. 10 ,support structure 164 may be a rigid frame orframework defining openings 167 therein.Support structure 164 may also be a screen or lattice-like structure or a solid ring to which an adhesive film is attached, as will be described below.Support structure 164 may be injection molded or may be assembled from a plurality of sealed-together porous or solid sheets to form a composite structure having the desired rigidity to receive and align withdrug delivery device 10. -
Adhesive module 160 further includes anadhesive film 166 attached (adhered) and conformed to supportstructure 164 as shown inFIGS. 8-10 to provide a single module.Adhesive film 166 includes a topnon-adhesive surface 168 and abottom surface 170 with adhesive applied thereon as a coating orlayer 172 of adhesive as shown inFIG. 9 . As also shown inFIG. 9 ,film 166 is conformed to supportstructure 164 withbottom surface 170 adhered to the solid or rigid portion ofsupport structure 164.Film 166 extends beyond theperipheral edge 174 ofstructure 164 and, oncedevice 10 is attached to the patient, beyond the outer edge ofperimeter 108 whereadhesive module 160 can be directly adhered to patient's skin as shown inFIG. 9 . - A further embodiment of an adhesive module in accordance with the present disclosure is shown in
FIGS. 11-13 . The embodiment ofadhesive module 180 inFIGS. 11-13 is, in many respects, similar to the above-described embodiment ofFIGS. 8-10 in thatadhesive module 180 likewise includes asupport structure 182. Thus,support structure 182 may be an internal frame or framework as shown inFIGS. 8-10 with afilm 184 conformed thereto, as best seen inFIG. 12 . More specifically,support structure 182 may be a frame orframework defining openings 183 therein.Support structure 182 may also be a screen or lattice-like structure or a solid ring to which anadhesive film 184 is attached, as will be described below.Support structure 182 may be injection molded or may be assembled from a plurality of sealed-together porous or solid sheets to form a composite structure having the desired rigidity to receive and align withdrug delivery device 10. -
Film 184 includes a top nonadhesive surface 186 and abottom surface 188 with adhesive applied thereon as a coating or layer. As shown inFIGS. 11 and 13 ,film 184 is adhered tohousing 90 and provides a full covering overdevice 10. As in earlier embodiments,film 184 extends beyond theperipheral edge 190 ofstructure 182 and, oncedevice 10 is attached to the patient, beyond the outer edge ofperimeter 108 whereadhesive module 180 can be directly adhered to patient's skin as shown inFIG. 12 . - As discussed above, application of the on-body drug delivery device described herein utilizes a “dual adhesive” approach, namely, an adhesive on the bottom surface of the
device substrate 10 and an adhesive on the bottom surface of the film that is part of theadhesive module FIGS. 7 and 11-13 ) or may contact a support structure (as in the embodiments ofFIGS. 8-14 ), the adhesive should have good adhesion to the materials used for thedevice 10 andsupport structures device 10 or a different material or materials. - In an alternative embodiment, rather than providing a single adhesive that is adequate for adhesion to both skin and non-skin surfaces, it is within the scope of the present disclosure for an adhesive module to include a plurality of different adhesives that are particularly configured for adhesion to either a skin or a non-skin surface. For example, an adhesive that is particularly well-suited to adhesion to a non-skin surface may be applied to a region of the adhesive module configured to engage the
device 10, while a different adhesive that is particularly well-suited to adhesion of a skin surface may be applied to a region of the adhesive module configured to engage the skin of the patient. An adhesive configured to engage a surface of thedevice 10 may be configured to be relatively weak (allowing for dissociation of the device and adhesive module) or strong (to discourage or prevent dissociation of the device and adhesive module). - In a further alternative embodiment of the adhesive module described above and shown in
FIGS. 11-13 , adhesive may be applied to only a portion of thebottom surface 188 offilm 184 which covers and overlies the drug delivery device. For example, the portion offilm 184 that covers the device (housing 90) may be free of adhesive. As seen, for example, inFIG. 14 adhesive 188 may be applied only to the outer peripheral region offilm 184 ofadhesive module 200 that is coincident withsupport structure 202 and in contact with the patient's skin. In a further variation of this embodiment, adhesive may be applied to a peripheral region of thebottom surface 188 offilm 184 that contacts only a portion ofsupport structure 202 and the patient's skin (not shown). In still a further variation of this alternative embodiment, adhesive may be applied only to that portion offilm 184 that contacts the skin of the patient (not shown). -
Films FIGS. 11-13 and 14 , film 184 (with or without adhesive) may conform closely to the contour of device (housing 90) as shown, for example, inFIG. 14 , Alternatively, film (with or without adhesive) may cover device (housing 90) in a less conforming manner as shown, for example, inFIG. 12 . Suitable film materials include, but are not limited to, polyethylene, polypropylene, polyurethanes, polyamides, polyesters, ethylene vinyl acetate, natural or synthetic polyisoprene, polybutadiene, polychloroprene, silicone, nitrile rubbers, nylon, olefin, and polyvinyl chloride. - The drug delivery devices described herein may be used to deliver any suitable fluid medication to a subject. In an exemplary embodiment, the methods and devices described herein are used to deliver pegfilgrastim to a subject, though other exemplary medications include (without limitation) one or more of the following: adalimiumab, rituximab, risankizumab, etanercept, trastuzumab, ado-trastuzumab emtansine, trastuzumab deruxtecan, bevacizumab, infliximab, pegfilgrastim, filgrastim, tocilizumab, golimumab, interferon beta-1a, ranibizumab, denosumab, pembrolizumab, nivolumab, aflibercept, eculizumab, ocrelizumab, pertuzumab, secukinumab, omalizumab, ustekinumab, vedolizumab, daratumumab, dupilumab, atezolizumab, natalizumab, bortezomib, ipilimumab, durvalumab, emicizumab, palivizumab, guselkumab, mepolizumab, panitumumab, ramucirumab, belimumab, abatacept, certolizumab pegol, ixekizumab, romiplostim, benralizumab, evolocumab, canakinumab, obinutuzumab, cetuximab, erenumab, blinatumomab, romosozumab, mirikizumab, inotuzumab, sacituzumab govitecan, enfortumab vedotin, brentuximab vedotin.
- It will be understood that the embodiments and examples described above are illustrative of some of the applications of the principles of the present subject matter. Numerous modifications may be made by those skilled in the art without departing from the spirit and scope of the claimed subject matter, including those combinations of features that are individually disclosed or claimed herein. For these reasons, the scope hereof is not limited to the above description but is as set forth in the following claims, and it is understood that claims may be directed to the features hereof, including as combinations of features that are individually disclosed or claimed herein.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/082,732 US20230117587A1 (en) | 2021-04-30 | 2022-12-16 | Wearable Injector with Adhesive Module |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/246,297 US11529459B1 (en) | 2021-04-30 | 2021-04-30 | Wearable injector with adhesive module |
US18/082,732 US20230117587A1 (en) | 2021-04-30 | 2022-12-16 | Wearable Injector with Adhesive Module |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/246,297 Division US11529459B1 (en) | 2021-04-30 | 2021-04-30 | Wearable injector with adhesive module |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230117587A1 true US20230117587A1 (en) | 2023-04-20 |
Family
ID=84492528
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/246,297 Active US11529459B1 (en) | 2021-04-30 | 2021-04-30 | Wearable injector with adhesive module |
US18/082,732 Pending US20230117587A1 (en) | 2021-04-30 | 2022-12-16 | Wearable Injector with Adhesive Module |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/246,297 Active US11529459B1 (en) | 2021-04-30 | 2021-04-30 | Wearable injector with adhesive module |
Country Status (1)
Country | Link |
---|---|
US (2) | US11529459B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD1010106S1 (en) * | 2021-09-27 | 2024-01-02 | Medtrum Technologies Inc. | Drug infusion device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080269657A1 (en) * | 2007-04-26 | 2008-10-30 | Isense Corporation | Adhesive overbandage |
US20180280609A1 (en) * | 2016-01-14 | 2018-10-04 | Terumo Kabushiki Kaisha | Application member and medical instrument |
US20190083702A1 (en) * | 2017-08-18 | 2019-03-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6692457B2 (en) | 2002-03-01 | 2004-02-17 | Insulet Corporation | Flow condition sensor assembly for patient infusion device |
US20040116866A1 (en) * | 2002-12-17 | 2004-06-17 | William Gorman | Skin attachment apparatus and method for patient infusion device |
US7070580B2 (en) | 2003-04-01 | 2006-07-04 | Unomedical A/S | Infusion device and an adhesive sheet material and a release liner |
EP1877116A1 (en) | 2005-04-13 | 2008-01-16 | Novo Nordisk A/S | Medical skin mountable device and system |
US9308325B2 (en) | 2006-06-19 | 2016-04-12 | Corium International, Inc. | Methods, devices, and kits for microjet drug delivery |
US20080125700A1 (en) | 2006-11-29 | 2008-05-29 | Moberg Sheldon B | Methods and apparatuses for detecting medical device acceleration, temperature, and humidity conditions |
GB0821492D0 (en) | 2008-11-25 | 2008-12-31 | Team Holdings Uk Ltd | Integrated auto-injector cartridge system |
US8608699B2 (en) | 2009-03-31 | 2013-12-17 | Tandem Diabetes Care, Inc. | Systems and methods to address air, leaks and occlusions in an insulin pump system |
WO2011026150A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Flexible mounting unit and cover for a medical device |
US8932256B2 (en) | 2009-09-02 | 2015-01-13 | Medtronic Minimed, Inc. | Insertion device systems and methods |
EA032537B1 (en) | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Method of operation of a drug delivery device |
EP3335747B1 (en) | 2011-10-14 | 2021-04-07 | Amgen Inc. | Injector and method of assembly |
ES2780395T3 (en) | 2012-11-21 | 2020-08-25 | Amgen Inc | Drug delivery device |
EP2968736A4 (en) | 2013-03-15 | 2016-11-09 | Amgen Inc | Body contour adaptable autoinjector device |
CN113559363B (en) | 2013-03-22 | 2023-10-31 | 美国安进公司 | Syringe and method of assembly |
AU2014274061C1 (en) | 2013-05-31 | 2019-06-13 | Mannkind Corporation | A fluid delivery device having an insertable prefilled cartridge |
EP2832390A1 (en) | 2013-07-30 | 2015-02-04 | Sensile Pat AG | Drug delivery device with needle actuation mechanism |
JP7051293B2 (en) | 2013-10-24 | 2022-04-11 | アムジエン・インコーポレーテツド | Drug delivery system with temperature sensing control |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
SG11201609219QA (en) | 2014-05-07 | 2016-12-29 | Amgen Inc | Autoinjector with shock reducing elements |
KR102506249B1 (en) | 2014-06-03 | 2023-03-03 | 암겐 인코포레이티드 | Drug delivery system and method of use |
KR20220053046A (en) | 2014-07-22 | 2022-04-28 | 암겐 인코포레이티드 | System and method for detecting activation of a medical delivery device |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (en) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | Drug delivery device with proximity sensor |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
CA2976047A1 (en) | 2015-02-10 | 2016-08-18 | Amgen Inc. | Rotationally biased insertion mechanism for a drug delivery pump |
ES2748750T3 (en) | 2015-02-17 | 2020-03-17 | Amgen Inc | Drug delivery device with vacuum assisted clamping and / or feedback |
WO2016141082A1 (en) | 2015-03-02 | 2016-09-09 | Unitract Syringe Pty Ltd | Device and method for making aseptic connections |
KR20170126976A (en) | 2015-03-09 | 2017-11-20 | 암겐 인코포레이티드 | Driving Mechanism for Drug Delivery Pump |
EP3162395A1 (en) | 2015-10-28 | 2017-05-03 | NNE Pharmaplan A/S | Single-use auto-injector |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
JOP20170042B1 (en) | 2016-02-12 | 2022-09-15 | Amgen Inc | Drug Delivery Device, Method of Manufacture and Method of Use |
EP3721922B1 (en) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3871708A3 (en) | 2016-05-26 | 2022-01-19 | Insulet Corporation | Wearable drug delivery system comprising a prefilled cartridge |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) * | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
JP7064501B2 (en) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | Drug delivery device with sterile fluid flow path and related assembly methods |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Needle insertion by overpressure |
JP2020509837A (en) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | Insertion mechanism for drug delivery device |
CN110446512B (en) | 2017-03-28 | 2022-03-18 | 美国安进公司 | Plunger rod and syringe assembly systems and methods |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (en) | 2017-06-22 | 2020-02-19 | Amgen Inc | Device activation impact/shock reduction. |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
BR112020000066B1 (en) | 2017-07-07 | 2021-07-06 | Neuroderm Ltd | DEVICE FOR SUBCUTANEOUS APPLICATION OF FLUID MEDICINE |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
MA49626A (en) | 2017-07-21 | 2020-05-27 | Amgen Inc | GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP3665612A1 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Image processing techniques for plunger depth measurement |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | Flow adapter for drug delivery device |
US11385140B2 (en) | 2017-10-06 | 2022-07-12 | Amgen Inc. | Testing assemblies and testing methods for drug delivery devices |
CN111132711B (en) | 2017-10-06 | 2022-07-01 | 安进公司 | Drug delivery device with interlocking components and related assembly methods |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
WO2019143753A1 (en) | 2018-01-17 | 2019-07-25 | Amgen Inc. | Drug delivery mechanism |
EP3762067A1 (en) | 2018-03-09 | 2021-01-13 | Amgen Inc. | Backflow prevention mechanism for drug delivery device |
-
2021
- 2021-04-30 US US17/246,297 patent/US11529459B1/en active Active
-
2022
- 2022-12-16 US US18/082,732 patent/US20230117587A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080269657A1 (en) * | 2007-04-26 | 2008-10-30 | Isense Corporation | Adhesive overbandage |
US20180280609A1 (en) * | 2016-01-14 | 2018-10-04 | Terumo Kabushiki Kaisha | Application member and medical instrument |
US20190083702A1 (en) * | 2017-08-18 | 2019-03-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
Non-Patent Citations (1)
Title |
---|
GrifGrips Doodlebug Combo: Adhesive Patches for CGM Devices. Available on Amazon.com. https://www.amazon.com/GrifGrips-Doodlebug-Combo-Adhesive-Patches/dp/B083G493QY?th=1 Date First Available: 12/16/2019 (Year: 2019) * |
Also Published As
Publication number | Publication date |
---|---|
US11529459B1 (en) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4581020A (en) | Medication delivery device and system for percutaneous administration of medication | |
US7879026B2 (en) | Controlled adjustment of medicine dispensation from an infusion pump device | |
US4685902A (en) | Disposable reservoir cassette | |
JP4658951B2 (en) | Medical device that can be worn on the skin | |
US20230117587A1 (en) | Wearable Injector with Adhesive Module | |
JP4540688B2 (en) | Fastening means for a wearable pharmaceutical injector used by being fastened to a living body | |
JP2009539444A (en) | An assembly comprising a device attachable to the skin and a package of the device | |
US20060217669A1 (en) | Device for securing a blood vessel cannula to a body | |
EP3433846A1 (en) | Injection training and compliance device and method | |
CA2629820A1 (en) | Implantable atraumatic medical site having a simplified design | |
US20190247623A1 (en) | Integrated sealing and securing device for vascular catheters and methods for use of same | |
US20140188074A1 (en) | Medical marking apparatus and methods | |
JP6549615B2 (en) | Infusion pump with program key | |
CA3080884A1 (en) | Medical device with adhesive patch and method for making same | |
US11311666B1 (en) | Modular wearable medicament delivery device and method of use thereof | |
US5968536A (en) | Device for applying topical anesthetic | |
US11497847B1 (en) | Wearable injector with adhesive substrate | |
US11426523B1 (en) | Drug delivery assembly including a removable cartridge | |
US11717608B1 (en) | Drug delivery assembly including an adhesive pad | |
US11607505B1 (en) | Wearable injector with sterility sensors | |
US11633537B1 (en) | Drug delivery assembly including a pre-filled cartridge | |
CA3223473A1 (en) | User removable fill closure tab with integrated membrane | |
US11344682B1 (en) | Drug supply cartridge with visual use indicator and delivery devices that use the same | |
US11419976B1 (en) | Wearable drug delivery device with pressurized fluid dispensing | |
CA1253762A (en) | Disposable reservoir cassette |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRESSLERGROUP, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHIFF, DAVID R.;BECHSTEIN, JUSTIN;REEL/FRAME:062126/0423 Effective date: 20210430 Owner name: FRESENIUS KABI DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRESSLERGROUP, INC.;REEL/FRAME:062126/0594 Effective date: 20210430 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |